- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line - FSHD is caused by aberrant activation of ...
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results